Javascript must be enabled to continue!
Abrogation of cisplatin‐induced nephrotoxicity by emodin in rats
View through CrossRef
AbstractNephrotoxicity of the anticancer drug cisplatin (CP) involves the generation of reactive oxygen species in renal cortex, and emodin (a rhubarb anthraquinone) has strong antioxidant and anticancer actions. Therefore, we tested here the possible ameliorative effect of emodin on CP nephrotoxicity in rats. Emodin was given orally (10 mg/kg/day for nine consecutive days), and on day 4, some of the treated rats were also injected intraperitoneally with either saline or CP (6 mg/kg). Five days after CP treatment, rats were killed, and blood and urine samples, and kidneys were collected for the assessment of histopathological renal damage and apoptosis, and for biochemical estimation of creatinine and urea concentrations in plasma and urine, several cytosolic antioxidant enzyme activities in kidneys, and urinalyses. CP significantly increased the concentrations of urea and creatinine, and decreased creatinine clearance. It also significantly reduced cortical glutathione concentration and the activity of superoxide dismutase. CP treatment significantly increased urine volume and N‐acetyl‐β‐D‐glucosaminidase activity and significantly decreased osmolarity and protein concentrations. Emodin treatment markedly and significantly mitigated all these effects. Sections from saline‐ and emodin‐treated rats showed apparently normal proximal tubules. However, kidneys of CP‐treated rats had a moderate degree of necrosis. This was markedly lessened when CP was given simultaneously with emodin. The concentration of CP in the cortical tissues was not significantly altered by emodin treatment. The results suggested that emodin had ameliorated CP nephrotoxicity in rats. Pending further pharmacological and toxicological studies emodin may be considered a potentially useful nephroprotective agent.
Title: Abrogation of cisplatin‐induced nephrotoxicity by emodin in rats
Description:
AbstractNephrotoxicity of the anticancer drug cisplatin (CP) involves the generation of reactive oxygen species in renal cortex, and emodin (a rhubarb anthraquinone) has strong antioxidant and anticancer actions.
Therefore, we tested here the possible ameliorative effect of emodin on CP nephrotoxicity in rats.
Emodin was given orally (10 mg/kg/day for nine consecutive days), and on day 4, some of the treated rats were also injected intraperitoneally with either saline or CP (6 mg/kg).
Five days after CP treatment, rats were killed, and blood and urine samples, and kidneys were collected for the assessment of histopathological renal damage and apoptosis, and for biochemical estimation of creatinine and urea concentrations in plasma and urine, several cytosolic antioxidant enzyme activities in kidneys, and urinalyses.
CP significantly increased the concentrations of urea and creatinine, and decreased creatinine clearance.
It also significantly reduced cortical glutathione concentration and the activity of superoxide dismutase.
CP treatment significantly increased urine volume and N‐acetyl‐β‐D‐glucosaminidase activity and significantly decreased osmolarity and protein concentrations.
Emodin treatment markedly and significantly mitigated all these effects.
Sections from saline‐ and emodin‐treated rats showed apparently normal proximal tubules.
However, kidneys of CP‐treated rats had a moderate degree of necrosis.
This was markedly lessened when CP was given simultaneously with emodin.
The concentration of CP in the cortical tissues was not significantly altered by emodin treatment.
The results suggested that emodin had ameliorated CP nephrotoxicity in rats.
Pending further pharmacological and toxicological studies emodin may be considered a potentially useful nephroprotective agent.
Related Results
Analysis of the pharmacokinetics and metabolism of aloe‐emodin following intravenous and oral administrations in rats
Analysis of the pharmacokinetics and metabolism of aloe‐emodin following intravenous and oral administrations in rats
AbstractAloe‐emodin, a natural polyphenolic anthraquinone, has shown various beneficial bioactivities in vitro. The aim of this study was to investigate the pharmacokinetics and me...
Coenzyme Q10 Attenuates Cisplatin-induced Nephrotoxicity Through Counteracting Oxidative Stress and Inflammation
Coenzyme Q10 Attenuates Cisplatin-induced Nephrotoxicity Through Counteracting Oxidative Stress and Inflammation
Background:
Cisplatin is an anticancer drug used in the management of solid tumors,
however, dose-related nephrotoxicity is one of its major problems. Agents having antioxidants, a...
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract
Cisplatin is the most commonly employed chemotherapeutic drug for ovarian cancer treatment. However, most ovarian cancer patients experience recurrent cispl...
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
RAD51C is a RAD51 paralog protein that mediates RAD51 filament formation on single-stranded DNA (ssDNA) in a canonical homologous recombination (HR) pathway. This step is vital for...
The potential beneficial effect of exenatide on cisplatin induced nephrotoxicity in non-diabetic rats
The potential beneficial effect of exenatide on cisplatin induced nephrotoxicity in non-diabetic rats
Background: Cisplatin is a major antitumor drug used for treatment of solid tumors. Nephrotoxicity is its main limiting side effect. Exenatide is described as an incretin mimetic p...
Progression of Cisplatin-Induced Nephrotoxicity in a Carnitine-Depleted Rat Model
Progression of Cisplatin-Induced Nephrotoxicity in a Carnitine-Depleted Rat Model
<i>Background:</i> This study has been initiated to investigate whether endogenous carnitine depletion and/or carnitine deficiency is an additional risk factor and/or a...
Honey feeding protects kidney against cisplatin nephrotoxicity through suppression of inflammation
Honey feeding protects kidney against cisplatin nephrotoxicity through suppression of inflammation
SummaryCisplatin is a highly effective chemotherapeutic drug used to treat a wide variety of solid tumors. However, its use was limited due its dose‐limiting toxicity to the kidney...
The effects of recombinant klotho in cisplatin‐induced ovarian failure in mice
The effects of recombinant klotho in cisplatin‐induced ovarian failure in mice
AbstractAimTo investigate whether recombinant klotho given concomitantly with cisplatin is effective in preventing cisplatin‐induced ovarian damage.MethodsThirty‐two adult female m...

